Angiogenesis Therapies

Li, William W.; Li, Vincent W.; Tsakayannis, Dimitris

doi:10.1007/978-1-59259-126-8_29

Cited by 7 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[240][241][242][243][244][245][246][247][248][249][250][251][252] Conservative estimates indicate that at least 40 pharmaceutical firms are developing angiogenesis inhibitors directed at these two targets with at least 27 drugs currently in clinical trials. [231,[253][254][255][256][257][258] Recently, a novel interaction between MMP-2 and integrin a v b 3 was observed by Cheresh et al when these proteins were found to colocalize on the surface of angiogenic blood vessels in vivo. [259] Integrin a v b 3 binds MMP-2, and this interaction is a requisite step in the cellular utilization of the enzyme on the surface of invasive endothelial cells.…”

Section: Reviewsmentioning

confidence: 93%

Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions

2003

View full text Add to dashboard Cite

The high-throughput synthesis and screening of compound libraries hold tremendous promise for drug discovery and powerful methods for both solid-phase and solution-phase library preparation have been introduced. The question of which approach (solution-phase versus solid-phase) is best for the preparation of chemical libraries has been replaced by which approach is most appropriate for a particular target or screen. Herein we highlight distinctions in the two approaches that might serve as useful considerations at the onset of new programs. This is followed by a more personal account of our own focus on solution-phase techniques for the preparation of libraries designed to modulate cellular signaling by targeting protein-protein or protein-DNA interactions. The screening of our libraries against a prototypical set of extracellular and intracellular targets, using a wide range of assay formats, provided the first small-molecule modulators of the protein-protein interactions studied, and a generalized approach for conducting such studies.

show abstract

Section: Reviewsmentioning

confidence: 93%

Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions

2003

View full text Add to dashboard Cite

show abstract

“…[240][241][242][243][244][245][246][247][248][249][250][251][252] Gegenwärtig entwickeln mindestens 40 pharmazeutische Unternehmen Angiogenese-Inhibitoren, die gegen diese beiden Targets gerichtet sind; mindestens 27 Wirkstoffe sind in klinischen Studien. [231,[253][254][255][256][257][258] Vor kurzem wurde von Cheresh et al eine neue Wechselwirkung zwischen MMP-2 und dem Integrin a v b 3 entdeckt: Beide Proteine befinden sich in vivo auf der Oberfläche durch tumorinduzierte Angiogenese gebildeter Blutgefäße. [259] Durch Bindung an das Integrin a v b 3 kann das Enzym MMP-2 auf der Oberfläche der invasiven endothelialen Zellen seine Wirkung entfalten.…”

Section: Target Protein-protein-wechselwirkungenunclassified

Kombinatorische Flüssigphasensynthese von Bibliotheken: auf der Suche nach Modulatoren für Protein‐Protein‐ und Protein‐DNA‐Wechselwirkungen in der zellulären Signaltransduktion

2003

View full text Add to dashboard Cite

Hochdurchsatzsynthese und ‐screening von Verbindungsbibliotheken haben große Erwartungen für die Wirkstoffsuche geweckt. Für die Herstellung solcher Bibliotheken an der Festphase und in Lösung sind leistungsfähige Methoden entwickelt worden. Die Synthesestrategie wird schon lange nicht mehr nach allgemeinen Erwägungen ausgewählt, sondern mit Blick auf die spezielle Fragestellung. In diesem Aufsatz beschreiben wir Unterschiede zwischen den beiden Methoden, die bei der Entwicklung neuer Programme helfen sollen. Als Beispiel beschreiben wir unsere Versuche, mithilfe von Lösungstechniken Modulatoren für zelluläre Signale durch Beeinflussung von Protein‐Protein‐ oder Protein‐DNA‐Wechselwirkungen zu identifizieren. Das Vorurteil, niedermolekulare Substanzen seien für therapeutische Intervention an solchen Zielstrukturen ungeeignet, konnten wir beim Screening unserer Bibliotheken gegen eine repräsentative Auswahl extrazellulärer und intrazellulärer Targets widerlegen: Mithilfe zahlreicher Testmethoden identifizierten wir die ersten niedermolekularen Modulatoren für Protein‐Protein‐Wechselwirkungen und erarbeiteten ein allgemeines Verfahren für derartige Untersuchungen.

show abstract

Antiangiogenic Therapy for Cancer: An Update

et al. 2012

View full text Add to dashboard Cite

The idea of anti-angiogenic therapy was the brain child of Dr. Judah Folkman in the early 1970s. He proposed that by cutting the blood supply off, cancer cells can be deprived of nutrients and hence treated. His efforts were paid off when Bevacizumab (Avastin®), a monoclonal antibody against the vascular endothelial growth factor (VEGF) was first approved for anti-angiogenic therapy in 2004 for the treatment of breast cancer. Since then, an array of anti-angiogenic inhibitors were developed, used in clinical trials and many got approved for use for the treatment of multiple cancers, alone or in combination with other cytotoxic/chemotherapy drugs. Despite this important breakthrough, anti-angiogenic therapy for cancer met with a number of hurdles on its way to be one of the options for cancer therapy. Herein, we summarize the latest update on the current knowledge on the mechanisms of tumor angiogenesis, pro- and anti-angiogenic factors, potential targets and their mechanisms of action, experimental evidences and the most recent data on the clinical trials on anti-angiogenic agents for cancer therapy.

show abstract

Angiogenesis Therapies

Cited by 7 publications

References 92 publications

Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions

Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions

Kombinatorische Flüssigphasensynthese von Bibliotheken: auf der Suche nach Modulatoren für Protein‐Protein‐ und Protein‐DNA‐Wechselwirkungen in der zellulären Signaltransduktion

Antiangiogenic Therapy for Cancer: An Update

Contact Info

Product

Resources

About